Cost-effectiveness of ten commonly used antipsychotics in first-episode schizophrenia in the UK: economic evaluation based on a de novo discrete event simulation model

阿米必利 利培酮 奎硫平 阿立哌唑 鲁拉西酮 奥氮平 成本效益 背景(考古学) 精神科 精神分裂症(面向对象编程) 医学 中止 抗精神病药 心理学 古生物学 风险分析(工程) 生物
作者
Junwen Zhou,A. Millier,Samuel Aballéa,C. François,Huajie Jin,Ryan C. Williams,Belinda Lennox,Apostolos Tsiachristas,Mondher Toumi
出处
期刊:British Journal of Psychiatry [Cambridge University Press]
卷期号:: 1-8
标识
DOI:10.1192/bjp.2024.251
摘要

Background Previous economic evidence about interventions for schizophrenia is outdated, non-transparent and/or limited to a specific clinical context. Aims We developed a de novo discrete event simulation (DES) model for estimating the cost-effectiveness of interventions in schizophrenia in the UK. Method The DES model was developed based on the structure of previous models, populated with demographic, clinical and cost data from the UK, and antipsychotics' effects from recent network meta-analyses. We simulated treatment pathways for patients with first-episode schizophrenia including events such as relapse, remission, treatment discontinuation, cardiovascular disease and death and estimated costs (2020£) taking the National Health Service perspective and quality-adjusted life years (QALYs) over ten years. Using the model, we ranked ten first-line antipsychotics based on their QALYs and cost-effectiveness. Results Amisulpride was associated with the highest QALYs, followed by risperidone long-acting injection (LAI), aripiprazole-LAI (6.121, 6.084, 6.070, respectively) and others (5.947–6.058). The most cost-effective antipsychotics were amisulpride, olanzapine and risperidone-LAI, with total probability of rankings of 1, ≤2, ≤3, that is, 95%, 89%, 80%, respectively; meanwhile, the least cost-effective were cariprazine, lurasidone and quetiapine, with total probability of rankings of 10, ≥9, ≥8, that is, 96%, 92%, 81%, respectively. Results were robust across sensitivity analyses and influenced primarily by relapse relevant parameters. Conclusions Our findings suggest amisulpride (or risperidone-LAI where oral treatment is inappropriate) as the best overall first-line option based on QALYs and cost-effectiveness. Our ranking may be used to guide decision-making between antipsychotics. Our model is open source and could be applied to the other settings.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小米完成签到,获得积分10
1秒前
ASCC完成签到 ,获得积分10
2秒前
Inner_Peace完成签到,获得积分10
3秒前
zhg完成签到 ,获得积分10
8秒前
雪山大地发布了新的文献求助10
9秒前
hdrizen完成签到,获得积分10
11秒前
Lucas的应助被369ninja采纳,获得10
12秒前
黙宇循光完成签到 ,获得积分10
13秒前
kelly完成签到 ,获得积分10
13秒前
weibo完成签到,获得积分10
14秒前
Chang完成签到 ,获得积分10
15秒前
刘一严完成签到 ,获得积分10
15秒前
16秒前
华华华完成签到,获得积分10
17秒前
19秒前
张张张发布了新的文献求助10
20秒前
科研猫完成签到,获得积分10
22秒前
神算子完成签到 ,获得积分10
23秒前
活泼雪莲发布了新的文献求助10
25秒前
妖精完成签到 ,获得积分10
26秒前
26秒前
wang完成签到,获得积分10
26秒前
茶缸子完成签到,获得积分10
28秒前
虎虎生威完成签到,获得积分10
29秒前
skywalker发布了新的文献求助10
31秒前
茶缸子01完成签到,获得积分10
33秒前
Monroe完成签到 ,获得积分10
34秒前
宋艳芳完成签到,获得积分10
35秒前
37秒前
歪歪发布了新的文献求助10
40秒前
js完成签到 ,获得积分10
40秒前
小yang发布了新的文献求助10
40秒前
橙子完成签到,获得积分20
41秒前
sobergod完成签到,获得积分10
44秒前
maolihui的应助被科研通管家采纳,获得10
44秒前
呆萌的若剑完成签到,获得积分10
45秒前
songrui643完成签到 ,获得积分10
46秒前
devilito完成签到,获得积分10
46秒前
leapper完成签到 ,获得积分10
48秒前
Lumos完成签到 ,获得积分10
54秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166538
求助须知:如何正确求助?哪些是违规求助? 9559535
关于积分的说明 21750645
捐赠科研通 7757337
什么是DOI,文献DOI怎么找? 3429141
关于科研通互助平台的介绍 2553521
邀请新用户注册赠送积分活动 2473904